WHO certified Barbados for eliminating mother-to-child HIV transmission as a public health problem. Here is what zero reported cases and 98% service coverage do—and do not—mean.
FDA granted accelerated approval to Voceryq to reduce surgery frequency in adults with RRP. Here is what the 7-of-26 no-surgery result—and the 32-person single-arm study—actually show.
A Missoula surveillance report estimated group A strep incidence was 106.1 times higher among people experiencing homelessness. Here is what the 36-person local finding does—and does not—show.
WHO set development targets for long-acting TB injections: one encounter for prevention and no more than three dosing visits for treatment. Here is what exists now—and what remains unproven.
Short answer: On October 26, 2026, the U.S. FDA approved talazoparib (Talzenna) with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer whose tumors have a homologous recombination repair (HRR) gene mutation detected by an FDA-authorized test. This is not an approval for every prostate cancer, and overall-survival data remain immature. Decision…
Short answer: On October 23, 2026, the U.S. FDA approved once-weekly basal insulin Awiqli (insulin icodec-abae) for people aged 10 years and older with type 2 diabetes. That does not mean every child using daily insulin can switch immediately. The pediatric evidence centered on 18 participants who received one dose, and the approval does not…
Short answer: WHO and ENHYPEN highlighted voluntary blood donation in Seoul on October 23, 2026, but the campaign did not change South Korea’s donor rules. A pledge or meeting the headline age and weight thresholds does not guarantee eligibility. Korean blood centers make the final decision after identity checks, a questionnaire, vital signs, hemoglobin testing,…
Short answer: France reported the first documented human infection with Shamonda virus (SHAV) on October 22, 2026. The patient was severely immunocompromised and died in early October, but investigators have not yet established how much the virus contributed to the death or exactly how the infection was acquired. One case does not show sustained human…
Short answer: The US Food and Drug Administration approved Hibsago (bepirovirsen) on October 20, 2026, as an add-on to existing antiviral therapy for a selected group of adults with chronic hepatitis B. In two phase 3 trials, about 19% met a laboratory-defined “functional cure” outcome 24 weeks after all hepatitis B treatment was stopped. That…
Short answer: On October 19, 2026, the US Food and Drug Administration gave Jemperli (dostarlimab) an accelerated approval for a narrowly defined group of adults with locally advanced rectal cancer. Some trial participants avoided surgery, radiation and other systemic treatment during the reported follow-up. The approval does not mean those treatments are unnecessary for every…
Short answer: The WHO–INTERPOL agreement announced on 16 October 2026 strengthens a framework for public-health and law-enforcement cooperation. It does not certify online pharmacies, announce a newly falsified medicine, or make every medicine sold online safe. The joint release describes how the two organizations intend to coordinate on cross-border threats; it does not set out…
Bottom line: On 14 October 2026, the U.S. Food and Drug Administration expanded the indication for Anktiva (nogapendekin alfa inbakicept-pmln) used with BCG. The added group is adults with BCG-unresponsive, high-grade, papillary-only non-muscle-invasive bladder cancer. This is not an approval for every type of bladder cancer or for everyone starting BCG. Which patients were added…